Literature DB >> 23192757

Evolution of reperfusion therapies for acute brain and acute myocardial ischemia: a systematic, comparative analysis.

Richa D Patel1, Jeffrey L Saver.   

Abstract

BACKGROUND AND
PURPOSE: Early reperfusion is the most effective therapy for both acute brain and cardiac ischemia. However, the cervicocephalic circulatory bed offers more challenges to recanalization interventions. The historical development of reperfusion interventions has not previously been systematically compared.
METHODS: Medline search identified all multi-arm, controlled trials of coronary revascularization for acute myocardial infarction and multicenter trials of cerebral revascularization for acute ischemic stroke reporting angiographic reperfusion rates.
RESULTS: Thirty-seven trials of coronary reperfusion enrolled 10 908 patients from 1983 to 2009, and 10 trials of cerebral reperfusion enrolled 1064 patients from 1992 to 2009. Coronary reperfusion trials included 10 of intravenous fibrinolysis alone, 8 combined intravenous fibrinolysis and percutaneous transluminal coronary angioplasty with or without stenting, 3 intra-arterial fibrinolysis, and 16 percutaneous transluminal coronary angioplasty with or without stenting. Cerebral reperfusion trials included 1 of intravenous fibrinolysis alone, 3 intra-arterial fibrinolysis, 3 endovascular device alone, and 3 of endovascular treatment ± intravenous fibrinolysis. In both circulatory beds, endovascular treatments were more efficacious at achieving reperfusion than peripherally administered fibrinolytics. In the coronary bed, rates of achieved reperfusion began at high levels in the 1980s and improved modestly over the subsequent 3 decades. In the cerebral bed, reperfusion rates began at modest levels in the early 1990s and increased more slowly. Most recently, in 2005 to 2009, cardiac reperfusion rates substantially exceeded cerebral, partial reperfusion 86.1% versus 61.1%, complete reperfusion 78.6% versus 23.4%.
CONCLUSIONS: Reperfusion therapies developed more slowly and remain less effective for cerebral than cardiac ischemia. Further, cerebral circulation-specific technical advances are required for physicians to become as capable at safely restoring blood flow to the ischemic brain as the ischemic heart.

Entities:  

Mesh:

Year:  2012        PMID: 23192757     DOI: 10.1161/STROKEAHA.112.666925

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

1.  Stent Retriever-Mediated Manual Aspiration Thrombectomy for Acute Ischemic Stroke.

Authors:  Ashutosh P Jadhav; Amin Aghaebrahim; Anat Horev; Dan-Victor Giurgiutiu; Andrew F Ducruet; Brian Jankowitz; Tudor G Jovin
Journal:  Interv Neurol       Date:  2016-10-07

2.  The 2012 Feinberg Lecture: treatment swift and treatment sure.

Authors:  Jeffrey L Saver
Journal:  Stroke       Date:  2012-12-13       Impact factor: 7.914

3.  Symptom differences and pretreatment asymptomatic interval affect outcomes of stenting for intracranial atherosclerotic disease.

Authors:  M D Alexander; P M Meyers; J D English; T R Stradford; S Sung; W S Smith; V V Halbach; R T Higashida; C F Dowd; D L Cooke; S W Hetts
Journal:  AJNR Am J Neuroradiol       Date:  2014-03-27       Impact factor: 3.825

Review 4.  Inductive and Deductive Approaches to Acute Cell Injury.

Authors:  Donald J DeGracia; Fika Tri Anggraini; Doaa Taha Metwally Taha; Zhi-Feng Huang
Journal:  Int Sch Res Notices       Date:  2014-10-13

5.  (‑)‑Epicatechin protects against myocardial ischemia‑induced cardiac injury via activation of the PTEN/PI3K/AKT pathway.

Authors:  Jia-Wen Li; Xiao-Yun Wang; Xin Zhang; Lei Gao; Li-Feng Wang; Xin-Hua Yin
Journal:  Mol Med Rep       Date:  2018-04-12       Impact factor: 2.952

6.  New Class of Radially Adjustable Stentrievers for Acute Ischemic Stroke: Primary Results of the Multicenter TIGER Trial.

Authors:  Rishi Gupta; Jeffrey L Saver; Elad Levy; Osama O Zaidat; Dileep Yavagal; David S Liebeskind; Ahmad Khaldi; Bradley Gross; Michael Lang; Sandra Narayanan; Brian Jankowitz; Kenneth Snyder; Adnan Siddiqui; Jason Davies; Eugene Lin; Ameer Hassan; Ricardo Hanel; Amin Aghaebrahim; Ritesh Kaushal; Ali Malek; Nils Mueller-Kronast; Robert Starke; Hormozd Bozorgchami; Gary Nesbit; Masahiro Horikawa; Ryan Priest; Jesse Liu; Ronald F Budzik; Peter Pema; Nirav Vora; M Asif Taqi; Edgar Samaniego; Qingliang Tony Wang; Erez Nossek; Guilherme Dabus; Italo Linfante; Ajit Puri; Eitan Abergel; Sidney Starkman; Satoshi Tateshima; Ashutosh P Jadhav
Journal:  Stroke       Date:  2021-03-19       Impact factor: 7.914

Review 7.  Complement in the Homeostatic and Ischemic Brain.

Authors:  Ali Alawieh; Andrew Elvington; Stephen Tomlinson
Journal:  Front Immunol       Date:  2015-08-12       Impact factor: 7.561

8.  Adverse impact of diet-induced hypercholesterolemia on cardiovascular tissue homeostasis in a rabbit model: time-dependent changes in cardiac parameters.

Authors:  Attila Kertész; Mariann Bombicz; Daniel Priksz; Jozsef Balla; Gyorgy Balla; Rudolf Gesztelyi; Balazs Varga; David D Haines; Arpad Tosaki; Bela Juhasz
Journal:  Int J Mol Sci       Date:  2013-09-17       Impact factor: 5.923

9.  Treatment of Human Urinary Kallidinogenase Combined with Maixuekang Capsule Promotes Good Functional Outcome in Ischemic Stroke.

Authors:  Juexian Song; Yi Lyu; Miaomiao Wang; Jing Zhang; Li Gao; Xiaolin Tong
Journal:  Front Physiol       Date:  2018-02-12       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.